4884
Kringle Pharma,Inc.
クリングルファーマ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Sep 2021
289,756
Sep 2022
391,829
Sep 2023
69,250
Sep 2024
80,038
Sep 2025
72,215
Operating profit(thousand JPY)
Sep 2021
-357,880
Sep 2022
-426,165
Sep 2023
-888,762
Sep 2024
-817,882
Sep 2025
-909,452
Operating profit margin(%)
Sep 2021
-123.51
Sep 2022
-108.76
Sep 2023
-1,283.41
Sep 2024
-1,021.87
Sep 2025
-1,259.37
Profit before tax(thousand JPY)
Sep 2021
-299,676
Sep 2022
-330,339
Sep 2023
-852,660
Sep 2024
-754,961
Sep 2025
-914,755
Profit(thousand JPY)
Sep 2021
-301,166
Sep 2022
-331,829
Sep 2023
-854,151
Sep 2024
-756,453
Sep 2025
-916,255
Total assets(thousand JPY)
Sep 2021
2,635,625
Sep 2022
3,208,691
Sep 2023
2,618,657
Sep 2024
2,757,113
Sep 2025
2,079,363
Cash and cash equivalents(thousand JPY)
Sep 2021
2,137,520
Sep 2022
2,502,046
Sep 2023
1,761,239
Sep 2024
1,816,943
Sep 2025
991,296
Cash flows from operating activities(thousand JPY)
Sep 2021
-560,922
Sep 2022
15,796
Sep 2023
-689,095
Sep 2024
-661,166
Sep 2025
-755,782
Cash flows from investing activities(thousand JPY)
Sep 2021
-
Sep 2022
-254,383
Sep 2023
-120,875
Sep 2024
-121,363
Sep 2025
-154,006
Cash flows from financing activities(thousand JPY)
Sep 2021
595,904
Sep 2022
603,112
Sep 2023
69,164
Sep 2024
838,233
Sep 2025
84,141
Return on equity(-)
Sep 2021
-
Sep 2022
-
Sep 2023
-
Sep 2024
-
Sep 2025
-
Equity ratio(%)
Sep 2021
95.1
Sep 2022
86.8
Sep 2023
76.6
Sep 2024
75.8
Sep 2025
61.5
Earnings per share(JPY per share)
Sep 2021
-72.51
Sep 2022
-68.33
Sep 2023
-158.46
Sep 2024
-118.21
Sep 2025
-133.92
Net assets per share(JPY per share)
Sep 2021
578.17
Sep 2022
517.75
Sep 2023
363.45
Sep 2024
306.87
Sep 2025
182.3
Dividend per share(-)
Sep 2021
-
Sep 2022
-
Sep 2023
-
Sep 2024
-
Sep 2025
-
Payout ratio(-)
Sep 2021
-
Sep 2022
-
Sep 2023
-
Sep 2024
-
Sep 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.